Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER vs AMINOSYN 10%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Travasol 4.25% in Dextrose 15% is a combination of amino acids and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis, while dextrose provides a source of calories. The mechanism involves intravenous administration bypassing the gastrointestinal tract to deliver nutrients directly into the bloodstream, supporting tissue repair, growth, and metabolic functions.
Aminosyn 10% provides a mixture of essential and non-essential amino acids to support protein synthesis and maintain nitrogen balance in patients unable to tolerate adequate oral or enteral nutrition. Each amino acid serves as a substrate for protein synthesis, hormone production, and other metabolic processes.
Parenteral nutrition for patients unable to obtain adequate nutrition orally or enterally,Adjunct to oral or enteral nutrition when intake is insufficient,Metabolic support in catabolic states such as major surgery, trauma, or burns
Parenteral nutrition for patients with inadequate oral or enteral intake,Prevention of nitrogen loss in catabolic states,Treatment of negative nitrogen balance
Intravenous infusion; typical adult dose is 500 m L to 1000 m L per day, administered at a rate of 200 m L/hour, adjusted based on metabolic and fluid needs.
Intravenous infusion: 1-1.5 g/kg/day (as amino acids), typically 500 m L of 10% solution (50 g amino acids) over 8-12 hours daily.
Not applicable as a single entity; components have intrinsic half-lives. Amino acids: rapid distribution (minutes), with terminal elimination of metabolites (e.g., urea) ~4-8 hours. Dextrose: half-life ~1-2 hours in steady state.
Amino acids: 0.5-1 hour for free amino acids; terminal half-life of infused nitrogen is approximately 2-4 hours; clinical context: reflects rapid uptake and metabolism.
The amino acids in Travasol are metabolized via various pathways including transamination, deamination, and urea cycle in the liver and other tissues. Dextrose undergoes glycolysis and oxidative phosphorylation to produce ATP.
Amino acids are metabolized primarily in the liver via deamination, transamination, and other pathways. The carbon skeletons enter the citric acid cycle or gluconeogenesis, and nitrogen is converted to urea.
TRAVASOL 4.25% IN DEXTROSE 15% (amino acids and dextrose) is a parenteral nutrition solution. Amino acids are metabolized to urea, which is excreted renally; dextrose is metabolized to CO2 and water. No significant biliary/fecal elimination.
Renal (primarily as amino acids and metabolites); ~90% of infused amino nitrogen is excreted renally within 24-48 hours; <5% biliary/fecal.
Amino acids: minimal to no protein binding (<10%). Dextrose: not protein bound.
Amino acids: negligible protein binding (<5%); albumin binds some tryptophan and branched-chain amino acids minimally.
Total body water distribution: ~0.55 L/kg for amino acids; dextrose distributes in extracellular fluid (~0.2 L/kg).
Amino acids: 0.3-0.5 L/kg (approximates extracellular fluid volume); clinical meaning: distributes primarily in ECF.
IV: 100% bioavailability; not administered orally or via other routes.
Intravenous: 100% (only route of administration); not absorbed orally as parenteral formulation.
In acute kidney injury or chronic kidney disease with GFR <30 m L/min, reduce volume and rate; monitor for electrolyte imbalances; consider avoidance in severe renal impairment.
GFR <50 m L/min: reduce dose to 0.5-0.8 g/kg/day. GFR <15 m L/min: avoid or use with extreme caution, monitor serum amino acids.
No specific Child-Pugh based adjustments; use with caution in severe hepatic encephalopathy; monitor ammonia levels.
Child-Pugh class B: reduce dose by 50%. Child-Pugh class C: contraindicated due to risk of hepatic encephalopathy.
Dose based on weight: 2 to 6 g/kg/day of amino acids and 15 g/kg/day of dextrose; start at 2 g/kg/day of amino acids and titrate; typical infusion rate 100-200 m L/kg/day.
Neonates: 2-3 g/kg/day IV. Infants/children: 1.5-2.5 g/kg/day IV. Adjust based on metabolic status and growth.
Start at lower infusion rates (e.g., 100 m L/hour); monitor fluid balance, renal function, and electrolytes; reduce total volume to avoid fluid overload.
Initiate at low end of adult dose (1 g/kg/day IV), monitor renal function and adjust accordingly; consider reduced metabolic clearance.
None
None
Do not administer if solution is discolored or contains particulate matter,Use with caution in patients with renal impairment, hepatic failure, or metabolic disorders,Monitor fluid and electrolyte balance, blood glucose, and acid-base status,Risk of infections related to catheter use,Rebound hypoglycemia may occur upon abrupt discontinuation
Risk of hyperammonemia, especially in patients with hepatic impairment or inborn errors of urea cycle,Electrolyte imbalances may occur; monitor serum electrolytes frequently,Monitor for signs of infection at infusion site,Use caution in patients with renal impairment, as accumulation of amino acids may occur,May cause metabolic acidosis in certain patients
Hypersensitivity to any component,Inborn errors of amino acid metabolism,Severe hyperglycemia or hyperosmolar state,Severe electrolyte disturbances,Severe hepatic or renal failure
Hypersensitivity to any component,Inborn errors of amino acid metabolism (e.g., maple syrup urine disease, phenylketonuria),Severe hepatic failure with hyperammonemia,Severe renal failure without dialysis support,Patients with uncorrected electrolyte imbalances
No oral intake restrictions specific to this formulation as it is for parenteral use. However, if transitioning to oral feeding, coordinate with dietitian to avoid electrolyte imbalances or overfeeding.
No direct food interactions, but ensure adequate non-protein calorie intake (carbohydrates, fats) to prevent amino acid utilization for energy. Avoid concurrent use with high-protein oral diets without medical supervision. For patients with phenylketonuria (PKU), verify product composition as some contain phenylalanine.
No expected increase in fetal malformation risk; amino acids and dextrose are endogenous nutrients. However, electrolyte disturbances or hyperglycemia may occur and can affect fetal development. First trimester: theoretical risk from metabolic derangements. Second and third trimesters: fetal growth and metabolic monitoring recommended.
Aminosyn 10% is an amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with this formulation. In the first trimester, the risk of teratogenicity is theoretical; essential amino acids are necessary for fetal development, but excesses or imbalances may be harmful. During the second and third trimesters, supplementation may be beneficial for maternal and fetal nutrition, but potential risks include metabolic acidosis or electrolyte disturbances if not properly monitored.
Components are normal blood constituents and are transferred into breast milk in small amounts. Not expected to cause adverse effects in breastfed infants. M/P ratio not established.
Aminosyn 10% is not excreted into breast milk in significant amounts; its components are endogenous substances. The M/P ratio is not applicable as it is not a drug with active transport. Maternal use during breastfeeding is considered safe if the infusion is necessary for maternal health. No adverse effects on the nursing infant are expected.
Increased plasma volume and renal clearance in pregnancy may necessitate higher infusion rates to maintain adequate nutrition; individualize based on clinical response and laboratory parameters.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering amino acid clearance. However, no specific dose adjustments are established for Aminosyn 10%. Dosage should be individualized based on nitrogen balance, weight gain, and metabolic parameters. Close monitoring of amino acid levels and metabolic status is recommended to avoid toxicities or deficiencies.
TRAVASOL 4.25% IN DEXTROSE 15% is a high-osmolarity parenteral nutrition solution (approximately 1700 m Osm/L). Must be administered via central venous line to avoid thrombophlebitis. Monitor serum glucose, electrolytes, renal function, and liver enzymes frequently. Risk of hyperglycemia, especially in stressed patients; consider insulin coverage. Do not use as a peripheral line solution due to high osmolarity.
Use central line administration for concentrations >5% to reduce thrombophlebitis risk. Monitor serum electrolytes, BUN, glucose, and liver function tests frequently. Adjust infusion rate based on metabolic tolerance; start at 100 m L/hr and increase gradually. Contraindicated in severe hepatic disease, uremia, or maple syrup urine disease. Do not use as a sole source of nutrition; provide concurrent calories from carbohydrates and fats.
This solution is given through a large vein in your chest, not a small vein in your arm.,You may need regular blood tests to check your blood sugar, kidney function, and mineral levels.,Report any signs of infection at the catheter site, such as redness, swelling, or pain.,Tell your healthcare provider if you feel unusually thirsty, urinate frequently, or have blurred vision.,Do not stop the infusion suddenly without medical advice.
This solution provides amino acids for protein building when you cannot eat normally.,Report signs of infection at catheter site: redness, swelling, pain, or drainage.,Common side effects include nausea, flushing, and warmth during infusion.,You will need regular blood tests to monitor kidney, liver, and metabolic function.,Inform your doctor if you have diabetes, kidney disease, or a history of gout.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER vs AMINOSYN 10%, answered by our medical review team.
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by Travasol 4.25% in Dextrose 15% is a combination of amino acids and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis, while dextrose provides a source of calories. The mechanism involves intravenous administration bypassing the gastrointestinal tract to deliver nutrients directly into the bloodstream, supporting tissue repair, growth, and metabolic functions.. AMINOSYN 10% is a Parenteral Nutrition Solution that works by Aminosyn 10% provides a mixture of essential and non-essential amino acids to support protein synthesis and maintain nitrogen balance in patients unable to tolerate adequate oral or enteral nutrition. Each amino acid serves as a substrate for protein synthesis, hormone production, and other metabolic processes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER and AMINOSYN 10% depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 500 m L to 1000 m L per day, administered at a rate of 200 m L/hour, adjusted based on metabolic and fluid needs.. The standard adult dose of AMINOSYN 10% is: Intravenous infusion: 1-1.5 g/kg/day (as amino acids), typically 500 m L of 10% solution (50 g amino acids) over 8-12 hours daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER and AMINOSYN 10% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER is classified as Category C. No expected increase in fetal malformation risk; amino acids and dextrose are endogenous nutrients. However, electrolyte disturbances or hyperglycemia may occur and can affect feta. AMINOSYN 10% is classified as Category C. Aminosyn 10% is an amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.